GlassScriptPhysician profile
Louis J Morledge
NPI 1093788838
$10,457.68
in general payments reported to CMS, 2019-2025
28 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $764 · 2021: $2,966 · 2022: $2,174 · 2023: $1,556 · 2024: $949 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,911.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,919.04 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,549.47 | 2021 | |
| Glaxosmithkline, LLC. | $937.18 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Viiv Healthcare Company | $921.41 | 2023-2025 | Apretude |
| Gilead Sciences, INC. | $704.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $631.77 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lundbeck LLC | $611.63 | 2022-2025 | Rexulti, Vyepti |
| Pfizer INC. | $541.09 | 2020-2025 | |
| Idorsia Pharmaceuticals US INC | $428.20 | 2022-2024 | Quviviq |
| Allergan, INC. | $292.41 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $287.25 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $270.12 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $269.61 | 2019-2023 | Trintellix |
| Emergent Biosolutions INC. | $212.02 | 2019 | |
| Exact Sciences Corporation | $165.35 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $129.74 | 2020-2022 | |
| Axsome Therapeutics, INC. | $126.64 | 2025 | Symbravo |
| Optinose US, INC. | $90.99 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $60.83 | 2021-2022 | |
| Covis Pharma Gmbh | $53.90 | 2021 | |
| Sanofi Pasteur INC. | $53.45 | 2019-2023 | |
| Boston Scientific Corporation | $51.32 | 2020 | |
| Almatica Pharma LLC | $37.06 | 2022-2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Seqirus USA INC | $29.44 | 2024-2025 | Flucelvax |
| Hologic Sales and Service, LLC | $24.80 | 2025 | Aptima |
| Bausch Health US, LLC | $24.36 | 2022 | |
| Dermira, INC. | $22.06 | 2020 | |
| Celltrion, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Morledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.